C4 Therapeutics to Present Preliminary Monotherapy Data From the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics to Present Preliminary Monotherapy Data From the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.
2024年7月16日，马萨诸塞州沃特敦市（GLOBE NEWSWIRE）——C4 Therapeutics，Inc.（C4T）（纳斯达克：CCCC）是一家临床阶段的生物制药公司，致力于推进靶向蛋白降解科学的发展。今天，该公司宣布，正在进行的CFT1946一期/二期临床试验单药剂量递增部分的初步数据，将作为迷你口头报告在2024年9月13日至17日于西班牙巴塞罗那举行的欧洲医学肿瘤学会（ESMO）2024年大会上发布，该药是一种面向突变BRAF V600实体肿瘤的新型BiDAC降解剂。
Details of the presentation are as follows:
演示的详细信息如下:
Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: Saturday, September 14, 2024, 2:45 – 2:50 CEST
Final Publication Number: 612MO
Session Category: Mini oral session
Session Title: Developmental therapeutics
Location: Oviedo Auditorium – Hall 3
Presenter: Maria Vieito, M.D., Msc (Barcelona, Spain, La Coruña)
标题：CFT1946一项治疗突变BRAF V600实体肿瘤的一期研究的初步结果
演示日期和时间：2024年9月14日，中欧夏令时2:45-2:50
最终出版号：612MO
会议类别：迷你口头会话
会议标题：发展性治疗
地点：奥维耶多礼堂-3号厅
演讲者：Maria Vieito万.D.，Msc（西班牙，拉科鲁尼亚，巴塞罗那）
About C4 Therapeutics
关于C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit .
C4 Therapeutics（C4T）（纳斯达克： CCCC）是一家临床前期制药公司，致力于通过有针对性的蛋白质降解科学来创造变革患者生命的新一代药物。C4T正在通过临床研究推进针对肿瘤的有针对性计划，并利用其TORPEDO平台来高效地设计和优化小分子药物来治疗难治性疾病。C4T的蛋白质降解药物旨在利用人体天然的蛋白质回收系统，快速降解引起疾病的蛋白质，有望克服药物耐受性，克服难以治疗的靶点并改善患者预后。要获得更多信息，请访问 .
About CFT1946
关于CFT1946
CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including colorectal cancer, melanoma and non-small cell lung cancer. More information about this trial may be accessed at (identifier: NCT05668585).
CFT1946是一种口服可用的BiDAC降解剂，旨在对BRAF V600X突变靶点进行强力和选择性瞄准。在临床前研究中，CFT1946在对BRAF V600E驱动疾病和对BRAF抑制剂具有抗药性的模型中，体内外均表现活性。CFT1946目前正在进行一项BRAF V600X突变实体瘤包括结直肠癌、黑色素瘤和非小细胞肺癌的一期剂量递增研究。有关此试验的更多信息可在网址（标识符：NCT05668585）上获得。
Contacts:
联系人：
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
投资者：
Courtney Solberg
投资者关系高级经理
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
媒体:
Loraine Spreen
董事高级负责人，公司通信和患者倡导。
LSpreen@c4therapeutics.com